CRYOABLATION VS RFA
VS MICROWAVE ABLATION
Three image-guided ablation technologies — cryoablation, radiofrequency ablation, and microwave ablation — each with distinct mechanisms, clinical strengths, and optimal indications. Understanding the differences is essential to matching the right modality to your tumour.
analyticsAt a Glance
- check_circleCryoablation uses extreme cold (–40°C to –150°C); RFA and MWA use heat (60–100°C+) to destroy tumour cells
- check_circleCryoablation provides real-time ice-ball visualisation on CT/MRI — a monitoring advantage over heat-based methods
- check_circleMWA achieves the largest ablation zones fastest; RFA has the most established guideline evidence; cryoablation excels near vessels
- check_circleModality selection depends on tumour site, size, proximity to structures, and patient factors — not a single universal preference
The Three Primary Ablation Technologies Explained
Image-guided tumour ablation uses energy delivered through a needle-sized probe to destroy cancer cells in situ — without surgical removal of tissue. Three technologies dominate current clinical practice: cryoablation (extreme cold), radiofrequency ablation (electrical heat), and microwave ablation (electromagnetic heat).
“No single ablation modality is universally superior — the right choice depends on the tumour's location, size, adjacency to critical structures, and the patient's prior treatment history.”
Cold vs Heat: The Fundamental Divide
Cryoablation generates lethal temperatures below –40°C through argon-gas expansion. RFA and MWA both destroy tissue through heat — RFA via ionic friction from alternating current (60–100°C), and MWA via dielectric heating from microwave energy (up to 150°C). Cold and heat produce similar cell death through different pathways.
When Modality Selection Matters Most
All three modalities achieve comparable local control for small (<2 cm) tumours far from critical structures. Modality selection becomes clinically decisive for larger lesions, perivascular tumours, lesions adjacent to bile ducts or bowel, and cases where intraprocedural monitoring or nerve protection is critical.
Local Tumour Control: Head-to-Head Data
Direct comparative data between modalities is limited, but the following reflects pooled evidence from meta-analyses and large prospective series for the most studied application — hepatocellular carcinoma.
HCC ≤2 cm: Local Recurrence-Free Rate at 3 Years
Pooled from Cho et al. Radiology 2023 meta-analysis; values approximate across included trials
- Microwave Ablation (MWA)88–92%
- Cryoablation85–90%
- Radiofrequency Ablation (RFA)82–88%
HCC 2–5 cm: Local Recurrence-Free Rate at 3 Years
Comparative estimates from multicentre registry data; larger lesions favour MWA volume advantage
- Microwave Ablation (MWA)75–82%
- Cryoablation (multi-probe)70–78%
- Radiofrequency Ablation (RFA)62–72%
Detailed Modality Comparison: Cryoablation vs RFA vs MWA
A structured comparison across the parameters that most influence modality selection in clinical practice.
| Parameter | Cryoablation | RFA | MWA |
|---|---|---|---|
| Mechanism | Argon-gas expansion: freeze to –150°C | Alternating current: heat to 60–100°C | Electromagnetic energy: heat to 60–150°C |
| Ablation zone monitoring | Direct visualisation on CT/MRI (ice-ball) | Inferred from impedance/temperature sensors | Limited real-time monitoring; post-ablation CT |
| Perivascular lesions | Excellent — heat sink does not apply to cold | Limited — large vessels dissipate heat | Better than RFA; fast heating limits heat sink |
| Max ablation zone size | 3–5 cm per probe; scalable with multi-probe | 2–3 cm per electrode; limited scaling | 3–5 cm per antenna; fast large zone creation |
| Procedural time | 60–90 min (two freeze-thaw cycles) | 20–40 min | 20–40 min |
| Intraprocedural pain | Lower — cold analgesia | Higher — heat-mediated pain | Moderate — similar to RFA |
| Immune stimulation | Strong — intact antigen release | Minimal — protein denaturation | Minimal — protein denaturation |
| Bile duct proximity | Safer — cold; can use biliary warming | Risk of biloma with <1 cm proximity | Moderate risk; heat containment unpredictable |
| Guideline recommendation | Selected cases; RFA-unsuitable tumours | Primary recommendation (EASL, BCLC) | Emerging preferred for larger lesions |
| Equipment cost | Higher (argon/helium consumables) | Moderate | Moderate-high (antenna cost) |
Clinical Decision Guide: When to Choose Each Modality
Modality selection should be guided by tumour characteristics and clinical context — not institutional equipment availability alone.
Choose Cryoablation When…
The tumour is adjacent to a major hepatic vein, portal branch, or large vessel where heat dissipation would compromise RFA/MWA coverage. The patient is medically frail and benefits from lower intraprocedural pain under lighter sedation. Nerve or critical structure monitoring is needed (e.g. spine, brachial plexus). Immunotherapy is being combined — cryoablation's immunogenic antigen release is a strategic advantage. Multiple probes are needed to cover an irregular lesion shape.
Choose RFA When…
The tumour is small (<2 cm), well-defined, and away from major vessels. A guideline-concordant option is needed — RFA has the most mature Level 1 evidence and is the named ablation modality in EASL/BCLC for HCC and NICE guidance for colorectal liver metastases. Procedural time needs to be minimised. The centre has more experience with RF than cryo or microwave.
Choose MWA When…
The target lesion is 3–5 cm and requires a large ablation zone rapidly. Perivascular lesions are being treated and the team requires faster heating than RFA to overcome the heat sink effect. Lung tumours with ground-glass opacity components are targeted — MWA performs better in aerated lung than RFA. The centre has next-generation MWA systems with improved thermal control.
Key Numbers Across Modalities
Practical reference figures drawn from published ablation series and manufacturer specifications.
- –150°CCryoprobe tip minimum temperatureArgon gas expands at the probe tip via the Joule-Thomson effect to reach –150°C; the target tumour is exposed to –40°C or below.
- 100°CTarget tissue temperature for RFATemperatures above 60°C cause immediate protein denaturation; RFA targets 60–100°C within the tumour to ensure complete necrosis.
- 150°C+MWA tissue temperature at antenna tipMWA generates the highest tissue temperatures of the three modalities, enabling faster ablation of larger volumes.
- 5 mmRequired ablation margin beyond tumourAll three modalities aim for at least a 5 mm ablative margin — lesions near critical structures where this cannot be achieved have higher local recurrence rates.
More from the Cryoablation Therapy Resource Library
Explore the full cryoablation knowledge base — from procedure details to disease-specific applications and combination immunotherapy.
- Cryoablation Therapy — Complete Treatment Guide
- What to Expect During and After Cryoablation
- Complications of Cryoablation: Risk Profile and Management
- Cryoprobe Technology: Argon Systems and Multi-Probe Arrays
- Cryoablation for Liver Tumours: HCC and Metastases
- Cryoimmunotherapy: Combining Cryoablation with Checkpoint Inhibitors
Frequently Asked Questions
Common questions from patients comparing ablation modalities before their intervention.
Comparing the Modalities
My doctor mentioned RFA — should I ask about cryoablation instead?
If your tumour is small (<2 cm), well-positioned away from major vessels, and in an organ where RFA has strong guideline support (liver, kidney), RFA is a perfectly appropriate choice. However, if your tumour is adjacent to a major vessel, you have a perivascular HCC, or your lesion is in a location where the ice-ball's real-time visibility on CT/MRI would improve safety, asking about cryoablation is reasonable. CancerFax can arrange a second opinion from an interventional oncologist who performs all three modalities.
Is microwave ablation available in China and India?
Yes. Microwave ablation is widely available at major oncology centres in China and India — in fact, several Chinese manufacturers (including MedWaves and Nanjing AnYu Medical) produce MWA systems that are used domestically and exported globally. Both MWA and cryoablation are routinely performed alongside RFA at top-tier Chinese hepatology and interventional oncology centres accessible via CancerFax.
Does cryoablation hurt more than RFA?
In most patients, cryoablation is actually better tolerated during the procedure than RFA. Cold produces a natural analgesic effect on local nerve fibres, reducing intraprocedural pain. RFA's heat generates more intense pain signals. For post-procedural discomfort, both modalities are broadly similar — mild to moderate soreness at the probe site for 24–48 hours, managed with standard analgesics.
Can I have more than one type of ablation across different lesions?
Yes — combining modalities across different lesions in the same patient is clinically rational and practised at specialist centres. For example, an RFA-suitable lesion in one part of the liver may be treated with RFA at the same session as a perivascular lesion better suited to cryoablation. The treating interventional oncologist selects the optimal modality per lesion rather than applying one technology to all targets.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Which Ablation Modality Is Right for Your Case?
CancerFax reviews your imaging, tumour site, and clinical history to help identify the most appropriate ablation modality — and connects you with experienced interventional oncologists in China and India who perform all three technologies.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.